Consensus Cytokinetics, Incorporated

Equities

CYTK

US23282W6057

Market Closed - Nasdaq 04:00:00 2024-05-20 pm EDT 5-day change 1st Jan Change
60.6 USD +1.80% Intraday chart for Cytokinetics, Incorporated +4.68% -27.42%

Evolution of the average Target Price on Cytokinetics, Incorporated

Price target over the last 5 years

History of analyst recommendation changes

2b9831b5096562e0ff69410f69cdca.vWKDfqN2QbBdcXWUSSqviteo3WIn6eLcDIAOXeYJ_Ew._iPoLedDN8kVBxLtPB3l8OHMlCgUtpGvSdV4DYRmqxj1BNZMmgIt3h48PA~9b5fff402f27b19d8995dba32cf0c0af
Oppenheimer Adjusts Cytokinetics Price Target to $106 From $107, Maintains Outperform Rating MT
Cytokinetics Insider Sold Shares Worth $1,012,265, According to a Recent SEC Filing MT
Cytokinetics Insider Sold Shares Worth $2,422,918, According to a Recent SEC Filing MT
Mizuho Securities Adjusts Price Target on Cytokinetics to $99 From $103, Maintains Buy Rating MT
UBS Downgrades Cytokinetics to Neutral From Buy, Adjusts Price Target to $92 From $61 MT
Mizuho Securities Boosts Price Target on Cytokinetics to $103 From $80, Keeps Buy Rating MT
B. Riley Raises Cytokinetics' PT to $122 From $66, Keeps Buy Rating; Notes Heightened Conviction in Aficamten Taking Dominant Market Share Cardiac Myosin Inhibitor Market MT
Truist Securities Raises Cytokinetics' Price Target to $86 From $60, Buy Rating Kept MT
Needham Raises Cytokinetics' Price Target to $108 From $60, Keeps Buy Rating MT
HC Wainwright Raises Cytokinetics Price Target to $94 From $58, Maintains Buy Rating MT
Cantor Fitzgerald Raises Cytokinetics Price Target to $101 From $65, Maintains Overweight Rating MT
Goldman Sachs Starts Coverage on Cytokinetics with Buy Rating, $50 Price Target MT
B. Riley Initiates Cytokinetics With Buy Rating, $66 PT; Says Aficamten's Differentiation Remains Underappreciated MT
UBS Trims Cytokinetics' Price Target to $61 From $62, Keeps Buy Rating MT
HC Wainwright Adjusts Cytokinetics Price Target to $58 From $49, Maintains Buy Rating MT
Cantor Fitzgerald Adjusts Cytokinetics' Price Target to $65 From $59, Keeps Overweight Rating MT
SVB Initiates Cytokinetics at Outperform MT
JPMorgan Raises Cytokinetics' Price Target to $54 From $52, Maintains Overweight Rating MT
UBS Adjusts Cytokinetics Price Target to $62 From $61, Maintains Buy Rating MT
UBS Adjusts Cytokinetics Price Target to $61 From $67, Maintains Buy Rating MT
Cantor Fitzgerald Adjusts Price Target on Cytokinetics to $59 From $61, Maintains Overweight Rating MT
JPMorgan Chase Adjusts Price Target on Cytokinetics to $52 From $55, Maintains Overweight Rating MT
UBS Adjusts Cytokinetics' Price Target to $67 From $66, Maintains Buy Rating MT
Goldman Sachs Lowers Cytokinetics' Price Target to $48 From $56, Maintains Buy Rating MT
Needham Adjusts Price Target on Cytokinetics to $60 From $58, Maintains Buy Rating MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
18
Last Close Price
60.6 USD
Average target price
93.06 USD
Spread / Average Target
+53.56%
High Price Target
122 USD
Spread / Highest target
+101.32%
Low Price Target
70 USD
Spread / Lowest Target
+15.51%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Cytokinetics, Incorporated

Oppenheimer
Mizuho Securities
UBS
B. Riley
Truist Securities
Needham & Co.
HC Wainwright
Cantor Fitzgerald
Goldman Sachs
SVB Securities LLC
JPMorgan Chase
BofA Securities
JMP Securities
Raymond James
Morgan Stanley
Piper Sandler
Jefferies & Co.
Barclays
Wolfe Research
Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings
  1. Stock Market
  2. Equities
  3. CYTK Stock
  4. Consensus Cytokinetics, Incorporated
-40% Exceptional extension: Our subscriptions help you unlock the best investment opportunities.
BENEFIT NOW